Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
190 participants
INTERVENTIONAL
2008-04-30
2008-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Multicenter Study to Evaluate the Analgesic Efficacy of XP21L in Subjects With Pain Following Bunionectomy Surgery
NCT00366444
Multicenter Study to Evaluate the Analgesic Efficacy of XP21L in Subjects With Pain Following Bunionectomy Surgery
NCT00375934
XG005 for Pain Control in Subjects Undergoing Bunionectomy
NCT06017999
A Study of MDT-10013 in the Treatment of Acute Postoperative Pain Following Bunionectomy
NCT02077140
A Study to Evaluate Safety and Efficacy Following Dosing of Oxycodone/Naltrexone for Treatment of Adults With Pain Following Bunionectomy Surgery
NCT02401750
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A
Placebo
B
XP20B
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
XP20B
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* having achieved the requisite level of pain
Exclusion Criteria
* history of substance abuse
* clinically significant condition or lab abnormality
* taken any prohibited medications
* gastrointestinal bleeding or history of
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Xanodyne Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Xanodyne Pharmaceuticals
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Keith Moore, PharmD
Role:
Xanodyne Pharmaceuticals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Investigatve Site
Anaheim, California, United States
Investigative Site
Owings Mills, Maryland, United States
Investigative Site
Austin, Texas, United States
Investigative Site
Houston, Texas, United States
Investigative Site
San Marcos, Texas, United States
Investigative Site
Salt Lake City, Utah, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
XP20B-301
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.